TCW Group’s Kalaris Therapeutics KLRS Stock Holding History

TCW Group’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,768	Closed	-$951K	–	365
2021 Q1	$951K	Sell	1,768 -7,629	-81%	-$6.41M	0.01%	294
2020 Q4	$8.31M	Buy	+9,397	New	+$7.23M	0.07%	147

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCW Group's KLRS Position: Q2 2021 in Review

TCW Group sold out of Kalaris Therapeutics (KLRS) in Q2 2021, closing a stake of 1,768 shares — an estimated $951K sold.

TCW Group first reported a position in KLRS in Q4 2020 and held it in 2 quarters. The position peaked at $8.31M in Q4 2020. 84 funds tracked by Wall St. Rank hold KLRS as of Q2 2021.

TCW Group reported no remaining Kalaris Therapeutics position as of Q2 2021 after selling out during the quarter.
TCW Group sold 1,768 Kalaris Therapeutics shares in Q2 2021, an estimated $951K.
TCW Group first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 2 quarters.
TCW Group's Kalaris Therapeutics position peaked at $8.31M in Q4 2020.
84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2021.

Based on TCW Group's 13F filing for Q2 2021, filed 23 Jul 2021.